Literature DB >> 11563212

Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario.

J T Clarke1, D Amato, R B Deber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11563212      PMCID： PMC81418     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  13 in total

1.  Alglucerase for Gaucher's disease: dose, costs and benefits.

Authors:  E Beutler; A M Garber
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

2.  Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada.

Authors:  A S Detsky
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

Review 3.  Measurement of health state utilities for economic appraisal.

Authors:  G W Torrance
Journal:  J Health Econ       Date:  1986-03       Impact factor: 3.883

4.  Translating technology assessment into policy. Conceptual issues and tough choices.

Authors:  R B Deber
Journal:  Int J Technol Assess Health Care       Date:  1992       Impact factor: 2.188

5.  Setting health care priorities in Oregon. Cost-effectiveness meets the rule of rescue.

Authors:  D C Hadorn
Journal:  JAMA       Date:  1991-05-01       Impact factor: 56.272

6.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.

Authors:  A Laupacis; D Feeny; A S Detsky; P X Tugwell
Journal:  CMAJ       Date:  1992-02-15       Impact factor: 8.262

7.  Enzyme replacement therapy for Gaucher's disease: the early Canadian experience.

Authors:  J J MacKenzie; D Amato; J T Clarke
Journal:  CMAJ       Date:  1998-11-17       Impact factor: 8.262

8.  Bentham in a box: technology assessment and health care allocation.

Authors:  A R Jonsen
Journal:  Law Med Health Care       Date:  1986-09

9.  A general health policy model: update and applications.

Authors:  R M Kaplan; J P Anderson
Journal:  Health Serv Res       Date:  1988-06       Impact factor: 3.402

Review 10.  Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981
View more
  11 in total

1.  Priority setting for pharmaceuticals. The use of health economic evidence by reimbursement and clinical guidance committees.

Authors:  Anders Anell
Journal:  Eur J Health Econ       Date:  2004-02

2.  Policy alternatives for treatments for rare diseases.

Authors:  Abbas H Panju; Chaim M Bell
Journal:  CMAJ       Date:  2010-07-12       Impact factor: 8.262

3.  Gaucher disease: variability in phenotype among siblings.

Authors:  D Amato; T Stachiw; J T R Clarke; G E Rivard
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

4.  Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy.

Authors:  Joe T R Clarke
Journal:  CMAJ       Date:  2006-01-17       Impact factor: 8.262

Review 5.  Health technology funding decision-making processes around the world: the same, yet different.

Authors:  Tania Stafinski; Devidas Menon; Donald J Philippon; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2011-06       Impact factor: 4.981

6.  Ethics, policy, and rare genetic disorders: the case of Gaucher disease in Israel.

Authors:  Michael L Gross
Journal:  Theor Med Bioeth       Date:  2002

Review 7.  Current themes in molecular pediatrics: molecular medicine and its applications.

Authors:  Andrea Superti-Furga; Livia Garavelli
Journal:  Ital J Pediatr       Date:  2010-02-19       Impact factor: 2.638

8.  Media influence on Herceptin subsidization in Australia: application of the rule of rescue?

Authors:  Ross Mackenzie; Simon Chapman; Glenn Salkeld; Simon Holding
Journal:  J R Soc Med       Date:  2008-06       Impact factor: 5.344

Review 9.  A systematic review of moral reasons on orphan drug reimbursement.

Authors:  Bettina M Zimmermann; Johanna Eichinger; Matthias R Baumgartner
Journal:  Orphanet J Rare Dis       Date:  2021-06-30       Impact factor: 4.123

10.  Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease.

Authors:  Laura van Dussen; Marieke Biegstraaten; Carla E M Hollak; Marcel G W Dijkgraaf
Journal:  Orphanet J Rare Dis       Date:  2014-04-14       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.